Breakthroughs in cell therapy for heart disease: Focus on cardiosphere-derived cells

Mayo Clinic Proceedings

Volumn 89, Issue 6, 2014, Pages 850-858

  Marbán, Eduardo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; CARDIOSPHERE DERIVED CELL; CELL FUNCTION; CELL REGENERATION; CELL SURVIVAL; CELL THERAPY; CELL TYPE; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; MONONUCLEAR CELL; NONHUMAN; PATIENT SAFETY; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

ALBUMINS; CELL- AND TISSUE-BASED THERAPY; HEART DISEASES; HUMANS; POLYESTERS; STEM CELL TRANSPLANTATION; STEM CELLS; TREATMENT OUTCOME;

EID: 84904648212     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.02.014     Document Type: Conference Paper

References (55)

1. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statisticse2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.
2. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Nat Rev Cardiol. 2012;9(11):620-633.
3. Jhund PS, McMurray JJV. Heart failure after acute myocardial infarction: a lost battle in the war on heart failure? Circulation. 2008;118(20):2019-2021.
4. Koudstaal S, Jansen Of Lorkeers SJ, Gaetani R, et al. Concise review: heart regeneration and the role of cardiac stem cells. Stem Cells Transl Med. 2013;2(6):434-443.
5. Malliaras K, Kreke M, Marbán E. The stuttering progress of cell therapy for heart disease. Clin Pharmacol Ther. 2011;90(4):532-541.
6. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet. 2001;357(9252):279-280.
7. Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008;117(9):1189-1200.
8. Strauer BE, Brehm M, Zeus T, et al. Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction. Dtsch Med Wochenschr. 2001; 126(34-35):932-938.
9. Marbán E, Malliaras K. Mixed results for bone marrowederived cell therapy for ischemic heart disease. JAMA. 2012;308(22): 2405-2406.
10. Seeger FH, Rasper T, Fischer A, et al. Heparin disrupts the CXCR4/SDF-1 axis and impairs the functional capacity of bone marrow-derived mononuclear cells used for cardiovascular repair. Circ Res. 2012;111(7):854-862.
11. Zhang S, Sun A, Xu D, et al. Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials. Clin Cardiol. 2009;32(8):458-466.
12. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847-1857.
13. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895-904.
14. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence for therapeutic regeneration in the final 1-year results of the CADUCEUS trial. J Am Coll Cardiol. 2014;63(2):110-122.
15. Chimenti I, Smith RR, Li TS, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res. 2010;106(5): 971-980.
16. Hong KU, Li QH, Guo Y, et al. A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice. Basic Res Cardiol. 2013; 108(3):346.
17. Malliaras K, Li TS, Luthringer D, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation. 2012;125(1): 100-112.
18. Marbán E, Cingolani E. Heart to heart: cardiospheres for myocardial regeneration. Heart Rhythm. 2012;9(10):1727-1731.
19. Harcourt HM. The American Heritage Dictionary of the English Language. http://ahdictionary.com. Accessed December 5, 2013.
20. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with STsegment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367(9505):113-121.
21. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115(7):896-908.
22. Davis DR, Zhang Y, Smith RR, et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One. 2009;4(9):7195.
23. Aghila Rani KG, Kartha CC. Effects of epidermal growth factor on proliferation and migration of cardiosphere-derived cells expanded from adult human heart. Growth Factors. 2010; 28(3):157-165.
24. Gaetani R, Ledda M, Barile L, et al. Differentiation of human adult cardiac stem cells exposed to extremely low-frequency electromagnetic fields. Cardiovasc Res. 2009;82(3):411-420.
25. Mishra R, Vijayan K, Colletti EJ, et al. Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation. 2011;123(4):364-373.
26. Takehara N, Tsutsumi Y, Tateishi K, et al. Controlled delivery of basic fibroblast growth factor promotes human cardiospherederived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol. 2008;52(23):1858-1865.
27. Tang YL, Zhu W, Cheng M, et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res. 2009;104(10):1209-1216.
28. Malliaras K, Smith RR, Kanazawa H, et al. Validation of contrastenhanced MRI to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction. Circulation. 2013;128(25):2764-2775.
29. Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126(11 suppl 1):S54-S64.
30. Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol. 2010;660:65-84.
31. Terrovitis JV, Smith RR, Marbán E. Assessment and optimization of cell engraftment after transplantation into the heart. Circ Res. 2010;106(3):479-494.
32. Lee ST, White AJ, Matsushita S, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol. 2011;57(4):455-465.
33. Stastna M, Chimenti I, Marbán E, Van Eyk JE. Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics. 2010; 10(2):245-253.
34. Li TS, Cheng K, Lee ST, et al. Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. Stem Cells. 2010;28(11):2088-2098.
35. Cheng K, Malliaras K, Li TS, et al. Magnetic enhancement of cell retention, engraftment and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion. Cell Transplant. 2012;21(6):1121-1135.
36. Tseliou E, Pollan S, Malliaras K, et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol. 2013;61(10):1108-1119.
37. Osman A. MicroRNAs in health and disease: basic science and clinical applications. Clin Lab. 2012;58(5-6):393-402.
38. Eulalio A, Mano M, Dal Ferro M, et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012;492(7429):376-381.
39. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012;11(11):860-872.
40. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 2000;113(19):3365-3374.
41. Sahoo S, Klychko E, Thorne T, et al. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res. 2011;109(7):724-728.
42. Iguchi H, Kosaka N, Ochiya T. Secretory microRNAs as a versatile communication tool. Commun Integr Biol. 2010;3(5): 478-481.
43. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014, in press.
44. Leistner D, Asmuss B, Erbs S, et al. Intracoronary infusion of bone marrow-derived mononuclear cells in acute myocardial infarction: 5 year clinical outcome and MRI data of the randomized, double-blind, placebo-controlled REPAIR-AMI trial. Circulation. 2011;124:A13940.
45. Zhang SN, Sun AJ, Ge JB, et al. Intracoronary autologous bone marrow stem cells transfer for patients with acute myocardial infarction: a meta-analysis of randomised controlled trials. Int J Cardiol. 2009;136(2):178-185.
46. Roes SD, Kelle S, Kaandorp TA, et al. Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol. 2007;100(6):930-936.
47. Schachinger V, Erbs S, Elsasser A, et al; REPAIR-AMI investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355(12): 1210-1221.
48. Huikuri HV, Kervinen K, Niemela M, et al; FINCELL Investigators. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J. 2008;29(22):2723-2732.
49. Tendera M, Wojakowski W, Ruzyllo W, et al; REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009;30(11):1313-1321.
50. Reffelmann T, Konemann S, Kloner RA. Promise of blood-and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol. 2009;53(4):305-308.
51. Lara PN, Redman MW. The hazards of randomized phase II trials. Ann Oncol. 2012;23(1):7-9.
52. Malliaras K, Marbán E. Moving beyond surrogate endpoints in cell therapy trials for heart disease. Stem Cells Transl Med. 2014;3(1):2-6.
53. Wilson JM. Medicine: a history lesson for stem cells. Science. 2009;324(5928):727-728.
54. Assmus B, Walter DH, Seeger FH, et al. Effect of shock wavefacilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA. 2013;309(15):1622-1631.
55. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23): 2329-2338.